Safety and reactogenicity of the BNT162b2 COVID-19 vaccine: Development, post-marketing surveillance, and real-world data

Safety and reactogenicity of the BNT162b2 COVID-19 vaccine: Development, post-marketing surveillance, and real-world data

ABSTRACTThe pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) led to urgent actions by innovators, vaccine developers, regulators, and other stakeholders to ensure public access to protective vaccines while maintaining regulatory agency standards. Although development t...

Full description

Bibliographic Details
Main Authors: Frank van den Ouweland, Nicola Charpentier, Özlem Türeci, Ruben Rizzi, Federico J. Mensa, Claudia Lindemann, Shanti Pather
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
SARS-CoV-2
safety
reactogenicity
vaccine development
post-marketing surveillance
real-world studies
Online Access:https://www.tandfonline.com/doi/10.1080/21645515.2024.2315659

Internet

https://www.tandfonline.com/doi/10.1080/21645515.2024.2315659

Similar Items